Has Matthew Sand, MD received payments from drug or device companies?

Yes. Drug and device makers reported $76,682 in general payments to Matthew Sand, MD across 569 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Sand, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Sand, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Sand, MD

Urology · Atlanta, GANPI 1679779664

Payments from drug & device makers

$76,682in general payments, 2019–2025

Across 569 payments — averaging $134.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Olympus America Inc.$34K
Richard Wolf Medical Instruments Corp.$9K
Ambu A/s$7K
Gyrus ACMI, Inc.$5K
Boston Scientific$4K
Olympus Latin America, Inc.$2K
plus $15K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Olympus America Inc.	68	$34,254
Richard Wolf Medical Instruments Corp.	7	$8,951
Ambu A/s	2	$7,129
Gyrus ACMI, Inc.	9	$4,859
Boston Scientific	61	$4,018
Olympus Latin America, Inc.	4	$2,220
Olympus Corporation	4	$1,665
Teleflex LLC	13	$1,370
Medtronic	22	$1,277
Coloplast	24	$957
Blue Earth Diagnostics	34	$743
AbbVie(2 entities)	34	$703
Sumitomo Pharma America, Inc.	36	$696
Astellas Pharma US Inc	31	$634
Procept Biorobotics Corporation	11	$594
Endo Pharmaceuticals Inc.	25	$508
Olympus Corporation Of The Americas	1	$370
Neotract Inc.	5	$357
Dornier Medtech America, Inc	3	$339
Ambu Inc.	3	$323
Dentsply IH AB	11	$295
Pfizer	15	$289
Bayer	13	$287
Palette Life Sciences, Inc.	3	$285
Endo USA, Inc.	10	$274
Stryker	2	$219
Urogen Pharma, Inc.	2	$187
Verity Pharmaceuticals Inc.	11	$172
Tolmar, Inc.	6	$170
Myovant Sciences Inc.	6	$169
Myriad Genetic Laboratories, Inc.	8	$163
Accord Healthcare, Inc.	1	$153
AstraZeneca	7	$147
KARL Storz Endoscopy-america	1	$143
Johnson & Johnson	4	$127
Axonics, Inc.	6	$126
Merck	4	$118
Laborie Medical Technologies Corp.	3	$112
C. R. Bard, Inc. & Subsidiaries	3	$111
Photocure Inc	1	$98
Urovant Sciences Inc	6	$97
Antares Pharma, Inc.	5	$86
180 Medical, Inc.	3	$84
Smith+Nephew	2	$78
Dentsply IH Inc.	5	$74
SRS Medical Systems, Inc.	1	$72
Angiodynamics, Inc.	2	$68
Ferring Pharmaceuticals Inc.	3	$63
Convatec Inc.	2	$60
Calyxo, Inc.	2	$55
Rochester Medical Corporation	2	$45
Agiliti Surgical, Inc.	2	$40
Novartis	2	$38
Baxter Healthcare	2	$37
Travere Therapeutics, Inc.	9	$36
Dendreon Pharmaceuticals LLC	1	$33
Progenics Pharmaceuticals, Inc.	1	$20
Integra Lifesciences Corporation	1	$20
LSI Solutions Inc	1	$19
Sun Pharmaceutical Industries Inc.	1	$19

How this compares

$76,682 in reported general payments places this provider in the 90th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia →

Medicare billing

Part B allowed, 2024

$291,282

Medicare patients

729

Services billed

2,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other urology in Atlanta

Viraj MasterAtlanta$2M
Vikram NarayanAtlanta$1.1M
Kenneth OganAtlanta$425K
Tariq HakkyAtlanta$140K
Shreyas JoshiAtlanta$98K
James BennettAtlanta$93K
Anthony BarnesAtlanta$89K
Brendan BrowneAtlanta$53K
John PattarasAtlanta$50K
Lindsey HartsellAtlanta$42K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →